Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088778 | 0.81 | KDM4E (0.42) | EPHX1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL2092086 | 0.81 | NPC1 (0.40) | EPHX1KDM4EALDH1A1POLBMEN1 | |
| SCHEMBL2091323 | 0.81 | IDO1 (0.40) | EPHX2EPHX1ALDH1A1POLBMEN1 | |
| SCHEMBL2094174 | 0.81 | GRIN2B (0.40) | EPHX2EPHX1ALDH1A1MEN1KMT2A | |
| SCHEMBL2090183 | 0.81 | EPHX2 (0.39) | EPHX2EPHX1TRPV1POLBMEN1 | |
| SCHEMBL2089169 | 0.79 | KMT2A (0.49) | EPHX2EPHX1TRPV1KDM4EALDH1A1 | |
| SCHEMBL2089248 | 0.78 | KMT2A (0.48) | EPHX2EPHX1TRPV1KDM4EALDH1A1 | |
| SCHEMBL2089520 | 0.73 | NPC1 (0.47) | EPHX2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL2091084 | 0.69 | NPC1 (0.45) | EPHX1KDM4EALDH1A1POLBMEN1 | |
| SCHEMBL30140846 | 0.66 | EPHX2 (0.69) | EPHX2EPHX1TRPV1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | SCANIO MARC J C (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163914-B2 | Modulate neuronal nicotinic receptor activity; attention deficit disorder, Parkinson's, Tourette's, schizophrenia, cognitive deficits, dementia; acute pain, post-surgical pain, chronic pain, inflammatory pain; 2-[1-azatricyclo[3.3.1.13,7]dec-4-ylidene]-N-(4-methylphenyl)acetamide | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2069346-B1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255179-A1 | Acetamide and Carboxamide Derivatives of Azaadamantane and Methods of Use Thereof | NAAA, AADAC, CD38 | EPHX2 995/4885EPHX1 1950/4885TRPV1 3412/4885 |
| US-20120190706-A1 | ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF | NAAA, AADAC, CD38 | EPHX2 995/4885EPHX1 1950/4885TRPV1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.